Founded in 2014, Glyscend aims to replicate the metabolic effects of bariatric surgery with safety advantages through its lead drug, a gut-restricted duodenal exclusion therapy. The company's goal is to provide patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia, while also providing endocrinologists and primary care physicians with innovative tools to treat the disease instead of merely managing it. Glyscend's technology is intended for the treatment of metabolic indications such as type 2 diabetes and other chronic conditions.